Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.7025 -0.0025 (-0.35%)
Streaming Delayed Price Updated: 9:39 AM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,488
Open 0.6930
Bid (Size) 0.7000 (150)
Ask (Size) 0.7050 (4)
Prev. Close 0.7050
Today's Range 0.6902 - 0.7025
52wk Range 0.6500 - 1.600
Shares Outstanding 56,769,091
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
-27.6%
-27.6%
1 Month
-19.1%
-19.1%
3 Month
-31.1%
-31.1%
6 Month
-17.5%
-17.5%
1 Year
-28.4%
-28.4%

More News

Read More
In today's session, these stocks are experiencing unusual volume.
Via Chartmill
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Here are the top movers in Thursday's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
The market is filled with gapping stocks in Thursday's session.
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul
Via Benzinga
Kronos Bio Announces CEO Transition and Reduction in Force
From Kronos Bio, Inc.
Via GlobeNewswire
Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining
Via Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
Via Benzinga
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
From Kronos Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Kronos Bio, Inc. - Common Stock publicly traded?
Yes, Kronos Bio, Inc. - Common Stock is publicly traded.
What exchange does Kronos Bio, Inc. - Common Stock trade on?
Kronos Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kronos Bio, Inc. - Common Stock?
The ticker symbol for Kronos Bio, Inc. - Common Stock is KRON on the Nasdaq Stock Market
What is the current price of Kronos Bio, Inc. - Common Stock?
The current price of Kronos Bio, Inc. - Common Stock is 0.7025
When was Kronos Bio, Inc. - Common Stock last traded?
The last trade of Kronos Bio, Inc. - Common Stock was at 05/16/25 09:39 AM ET
What is the market capitalization of Kronos Bio, Inc. - Common Stock?
The market capitalization of Kronos Bio, Inc. - Common Stock is 39.88M
How many shares of Kronos Bio, Inc. - Common Stock are outstanding?
Kronos Bio, Inc. - Common Stock has 40M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.